Form 4: Eloxx Pharmaceuticals Director Equity Transaction
Statement of Changes in Beneficial Ownership
Director Steven D. Rubin acquired common stock through the vesting of restricted stock units and was granted new stock options.
Summary
- Director Steven D. Rubin acquired 1,875 shares of common stock on January 24, 2026, through the vesting of restricted stock units (RSUs).
- Following the transaction, the director holds a total of 14,625 shares of common stock.
- The director was granted 179,854 stock options on September 19, 2025, with an exercise price of $0.15 per share.
- The options vest over a 36-month period starting October 31, 2025, subject to continuous service.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director equity compensation that does not signal a change in company strategy or financial health.
Positives
- Director maintains a long-term incentive alignment with the company through continued equity ownership and new option grants.
Negatives
- None identified in this filing.
Risks
- Vesting of options is contingent upon the director's continuous service to the issuer.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on director equity compensation and ownership changes.
Industry Context
StockSavvy.ai notes that this filing represents standard corporate governance and executive compensation activity within the biotechnology sector, where equity-based incentives are common to align director interests with long-term shareholder value.
Comparison to Industry Standards
- The use of RSU vesting and multi-year option vesting schedules is consistent with standard compensation practices for directors in small-cap pharmaceutical companies.
Stakeholder Impact
- Minimal impact on shareholders as this is a standard equity compensation event.
Next Steps
- Continued monthly vesting of stock options through September 2028.
Key Dates
| Date | Description |
|---|---|
| 09/19/2025 | Grant date of stock options |
| 10/31/2025 | Initial vesting date for stock options |
| 01/24/2026 | Vesting and acquisition of common stock via RSUs |
| 05/08/2026 | Filing date of the Form 4 |
| 09/19/2035 | Expiration date of stock options |
Keywords
Eloxx Pharmaceuticals, ELOX, Form 4, Insider Trading, Equity Compensation, Director Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.